Immediate Impact
60 standout
Citing Papers
Prostate Cancer
2025 Standout
Thirty years of NRF2: advances and therapeutic challenges
2025 Standout
Works of Ellen S. de Morrée being referenced
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer
2015
Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer
2014
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Ellen S. de Morrée | 389 | 172 | 122 | 177 | 10 | 537 | |
| Oliver Sartor | 479 | 102 | 136 | 172 | 23 | 624 | |
| Tanya K. Day | 253 | 261 | 45 | 162 | 15 | 561 | |
| Rana Sullivan | 310 | 47 | 250 | 82 | 19 | 621 | |
| R. Nevin Murray | 533 | 240 | 200 | 172 | 10 | 640 | |
| L A Speicher | 288 | 51 | 291 | 103 | 8 | 532 | |
| Allen Saliganan | 199 | 36 | 270 | 174 | 14 | 591 | |
| Erik Bovinder Ylitalo | 499 | 65 | 125 | 195 | 12 | 604 | |
| Avery Spitz | 364 | 53 | 143 | 74 | 12 | 465 | |
| Eric G. Bluemn | 480 | 53 | 98 | 192 | 8 | 609 | |
| Diana Bello | 256 | 19 | 134 | 118 | 12 | 573 |
All Works
Loading papers...